There is provided compositions and methods for modulating the fenestration porosity, fenestration frequency or fenestration diameter of liver endothelial cells. In particular compositions comprising conjugates of quantum dots and a therapeutic are used to modulate the fenestration porosity, frequency or diameter of liver endothelial cells.

The present invention provides methods and compositions for the treating a patient with a genetic disease, such as fibronectin glomerulopathy, hereditary coproporphyria and others. Methods and compositions are also provided for modulating the disease-associated gene(s) by altering gene signaling networks.

The present invention provides methods and compositions for the treating a patient with a genetic disease, such as fibronectin glomerulopathy, hereditary coproporphyria and others. Methods and compositions are also provided for modulating the disease-associated gene(s) by altering gene signaling networks.

Provided is a method for inducing innate apolipoprotein B editing catalytic protein (APOBEC) driven C>U RNA deamination of RNA in a cell comprising contacting the cell with an effective amount of atpenin A5 with or without interferon. Specifically, APOBEC3A is a cytidine deaminase enzyme that edits RNA transcripts of hundreds of cellular genes upon stimulation of innate immune cells by low oxygen tension (hypoxia) or antiviral factor interferon. Atpenin A5 induces APOBEC3A-mediated RNA editing in normoxia to levels comparable to those seen in hypoxia. The method can be used to treat viral conditions.

Provided is a method for inducing innate apolipoprotein B editing catalytic protein (APOBEC) driven C>U RNA deamination of RNA in a cell comprising contacting the cell with an effective amount of atpenin A5 with or without interferon. Specifically, APOBEC3A is a cytidine deaminase enzyme that edits RNA transcripts of hundreds of cellular genes upon stimulation of innate immune cells by low oxygen tension (hypoxia) or antiviral factor interferon. Atpenin A5 induces APOBEC3A-mediated RNA editing in normoxia to levels comparable to those seen in hypoxia. The method can be used to treat viral conditions.

Provided is a method for inducing innate apolipoprotein B editing catalytic protein (APOBEC) driven C>U RNA deamination of RNA in a cell comprising contacting the cell with an effective amount of atpenin A5 with or without interferon. Specifically, APOBEC3A is a cytidine deaminase enzyme that edits RNA transcripts of hundreds of cellular genes upon stimulation of innate immune cells by low oxygen tension (hypoxia) or antiviral factor interferon. Atpenin A5 induces APOBEC3A-mediated RNA editing in normoxia to levels comparable to those seen in hypoxia. The method can be used to treat viral conditions.

A pharmaceutical composition including an extruded solid and one or more pharmaceuticals or nutraceuticals is provided. The extruded solid includes hydroxypropylmethylcellulose acetate succinate and isomalt.

Provided herein are methods and compositions, including synergistic combinations, for the treatment of tuberculosis.

Provided herein are methods and compositions, including synergistic combinations, for the treatment of tuberculosis.

Provided herein are methods and compositions, including synergistic combinations, for the treatment of tuberculosis.